Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Analyst coverage

Analyst coverage

Firm Analyst
Barclays
 Peter Lawson, D. Phil.
Citi
 David Lebowitz
Cowen and Company
 Marc Frahm, Ph.D.
Goldman, Sachs & Co.
 Salveen Richter
Guggenheim Securities
 Michael Schmidt, Ph.D.
H.C. Wainwright
 Andrew Fein
JMP Securities
 Reni Benjamin, Ph.D.
J.P. Morgan
 Brian Cheng
Leerink
 Andrew Berens, M.D.
Morgan Stanley
 Michael Ulz
Needham & Company
 Ami Fadia
Oppenheimer & Co.
 Matthew Biegler
Piper Sandler
 Chris Raymond
Raymond James
 Laura Prendergast, Ph.D.
Robert W. Baird
 Colleen M. Kusy
Stephens & Co.
 Sudan Loganathan Ph.D.
Stifel
 Brad Canino
UBS
 David Dai
Wedbush PacGrow Life Sciences
 David Nierengarten, Ph.D.
Wells Fargo Securities
 Derek Archila
Blueprint Medicines Corporation is followed by the analysts listed on this page. Please note that any opinions, estimates or forecasts regarding Blueprint Medicines Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Blueprint Medicines Corporation or its management. Blueprint Medicines Corporation does not by its reference here or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.